Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

This important manuscript provides insights into the competition between Splicing Factor 1 (SF1) and Quaking (QKI) for binding at the ACUAA branch point sequence in a model intron, regulating exon ...

Hello, and welcome to the PG&E Corporation third-quarter 2024 earnings release conference call. Please note that this call is being recorded. (Operator Instructions) Thank you. I'd now like to turn ...

and who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

This important study advances our understanding of the way neurons in the auditory cortex of mice respond to unpredictable sounds. Through the use of state-of-the-art recording methods, compelling ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2024 are sufficient to meet estimated working capital requirements and fund current ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...